CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Platform Enabling the Development of RNA-based Immunotherapies
Montreal, Quebec, 26 September 2024 – Epitopea, a transatlantic cancer immunotherapy company, and CQDM are proud to announce the launch of a collaborative research project between Epitopea and Université de Montréal (UdeM), a leading Canadian research institution renowned for scientific innovation and technology transfer. Together, they will examine the feasibility of developing new immunotherapies to effectively treat patients with lung and ovarian cancers. This collaborative program was made possible by a grant of Canadian $1,499,457 from the government of Quebec.
